Trial in Extensive-Disease Small Cell Lung Cancer (ED-SCLC) Subjects Comparing Ipilimumab Plus Etoposide and Platinum Therapy to Etoposide and Platinum Therapy Alone

Randomized, Multicenter, Double-Blind, Phase 3 Trial Comparing the Efficacy of Ipilimumab Plus Etoposide/Platinum Versus Etoposide/Platinum in Subjects With Newly Diagnosed Extensive-Stage Disease Small Cell Lung Cancer (ED-SCLC)

Status

Unknown

Phases

Phase 3

Study type

Interventional

Source

JPRN

Registry ID

JPRN-jRCT2080222136

Enrollment

1100

Registered

2013-07-08

Start date

2013-07-08

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Small Cell Lung Carcinoma

Interventions

investigational material(s) Generic name etc : Ipilimumab (BMS-734016) INN of investigational material : Therapeutic category code : 429 Other antitumor agents Dosage and Administration for Investiga

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: Extensive-Stage Disease Small Cell Lung Cancer (ED-SCLC) Eastern Cooperative Oncology Group (ECOG) of 0 or 1

Exclusion criteria

Exclusion criteria: Prior systemic therapy for lung cancer Symptomatic Central Nervous System (CNS) metastases History of autoimmune disease

Design outcomes

Primary

Measure	Time frame
Overall Survival (OS) of subjects who received blinded study therapy	—

Secondary

Measure	Time frame
Overall Survival Immune-related Progression Free Survival (irPFS)	—

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026